Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
United Therapeutics Corporation - Common Stock
(NQ:
UTHR
)
478.16
-6.90 (-1.42%)
Streaming Delayed Price
Updated: 4:00 PM EST, Mar 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about United Therapeutics Corporation - Common Stock
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
United Therapeutics Corporation to Present at the Jefferies Healthcare Conference
June 03, 2022
From
United Therapeutics Corporation
Via
Business Wire
Short Volatility Alert: United Therapeutics Corporation
↗
May 26, 2022
On Wednesday, shares of United Therapeutics Corporation (NASDAQ: UTHR) experienced volatile short activity. After the activity, the stock price went up 4.31% to $228.39. The...
Via
Benzinga
United Therapeutics Stock Sees RS Rating Jump To 89; Earns 'Blue Dot'
↗
May 24, 2022
United Therapeutics stock had its Relative Strength (RS) Rating upgraded to 89 Tuesday, from 71 a day earlier.
Via
Investor's Business Daily
Expert Ratings for United Therapeutics
↗
May 24, 2022
Within the last quarter, United Therapeutics (NASDAQ:UTHR) has observed the following analyst ratings:
Via
Benzinga
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
↗
May 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
United Therapeutics Announces FDA Approval of Tyvaso DPI™
May 24, 2022
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics's Return on Invested Capital Insights
↗
May 18, 2022
According to Benzinga Pro, during Q1, United Therapeutics (NASDAQ:UTHR) earned $239.90 million, a 113.81% increase from the preceding quarter. United Therapeutics also posted a total of $461.90 million...
Via
Benzinga
7 Biotech Stocks With Key Catalysts for May
↗
May 11, 2022
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns.
Via
InvestorPlace
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
↗
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Recap: United Therapeutics Q1 Earnings
↗
May 04, 2022
United Therapeutics (NASDAQ:UTHR) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
United Therapeutics Corporation Reports First Quarter 2022 Financial Results
May 04, 2022
From
United Therapeutics Corporation
Via
Business Wire
Earnings Scheduled For May 4, 2022
↗
May 04, 2022
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Via
Benzinga
Earnings Outlook For United Therapeutics
↗
May 03, 2022
United Therapeutics (NASDAQ:UTHR) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that United...
Via
Benzinga
United Therapeutics Q1 2022 Earnings Conference Call On May 4, 2022 At 09:00 AM ET
↗
April 29, 2022
United Therapeutics (NASDAQ:UTHR) will host a conference call at 09:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. How to Attend United Therapeutics (UTHR) Conference Call Follow this...
Via
Benzinga
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the 2022 American Thoracic Society International Conference
April 29, 2022
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation to Report First Quarter 2022 Financial Results Before the Market Opens on Wednesday, May 4, 2022
April 27, 2022
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Announces the Publication of Tyvaso DPI™ BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation
April 06, 2022
From
United Therapeutics Corporation
Via
Business Wire
First Human With Pig Heart Transplant Dies: Reuters
↗
March 09, 2022
A 57-year-old man with terminal heart disease who became the first person to receive a genetically modified pig's heart has died, the University of Maryland Medical...
Via
Benzinga
10 Biggest Price Target Changes For Monday
↗
February 28, 2022
Barclays cut the price target on MasTec, Inc. (NYSE: MTZ) from $140 to $120. MasTec shares fell 0.1% to $79.00 in pre-market trading.
Via
Benzinga
Ferrer Announces Distribution Agreement With United Therapeutics for Treprostinil Inhalation Solution for Pulmonary Hypertension Associated With Interstitial Lung Disease
February 28, 2022
PH-ILD is a rare, serious, and progressive illness without an approved treatment in Europe and many other parts of the world
Via
Newswire.com
United Therapeutics Earnings Perspective: Return On Capital Employed
↗
February 25, 2022
Pulled from Benzinga Pro data, United Therapeutics (NASDAQ:UTHR) posted Q4 earnings of $112.20 million, an increase from Q3 of 31.04%. Sales dropped to $415.20 million, a 6.63%...
Via
Benzinga
FDA Pushes United Therapeutics-MannKind Tyvaso DPI's Decision Date; United Therapeutics' Q4 Misses Consensus
↗
February 24, 2022
United Therapeutics Corp (NASDAQ: UTHR) and its partner MannKind Corp (NASDAQ: MNKD) have received an FDA information request letter for additional...
Via
Benzinga
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2021 Financial Results
February 24, 2022
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics's Earnings Outlook
↗
February 23, 2022
United Therapeutics (NASDAQ:UTHR) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2021 Financial Results Before the Market Opens on Thursday, February 24, 2022
February 21, 2022
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces Historic Achievements in its Xenotransplantation Programs
January 21, 2022
From
United Therapeutics Corporation
Via
Business Wire
First Successful Pig Heart Transplant Into Human: Details On The Amazing Technology And A Public Company To Watch
↗
January 11, 2022
Pigs may not be able to fly, but they've provided a vital organ in a life-saving surgery for one U.S. man. What Happened: A Maryland hospital completed the first...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
January 11, 2022
Gainers Black Diamond Therapeutic (NASDAQ:BDTX) stock increased by 18.2% to $5.32 during Tuesday's pre-market session. The market value of their outstanding shares is...
Via
Benzinga
7 Pharmaceutical Stocks That Could Make You Rich
↗
January 06, 2022
Due to expiring patents and rising competition, successful pharmaceutical stocks need to develop robust drug pipelines. 7 Pharmaceutical Stocks That Could Make You Rich
Via
InvestorPlace
Mark To Market
↗
January 02, 2022
I thought that I would have a look at my own financial performance in 2021. In preview, I did alright, but not as well as the market. Let's take a look at what my portfolio held and how well it did.
Via
Talk Markets
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.